Recovery and results happen on different schedules

The first days call for easy movement and close checks

Check the treated joint and pelvis needle spot. Mild bruising can follow a marrow draw.

Spreading redness can't wait for a regular visit. Fever or leaking fluid also needs medical care.

Short, comfortable walks may be allowed. That doesn't clear you for a full workday.

Ask how much standing and lifting are safe. Get limits that match your usual day.

Keep the clinic number near you. You'll want it ready if soreness rises quickly.

Strength and activity return a little at a time

Your joint still needs strong muscles around it. The needle visit doesn't replace that support.

Ask when physical therapy can begin. You'll also need motions to avoid for now.

A flat walk is easier than a rocky climb. Add time or distance, but not both together.

If soreness rises and stays high, ease back. Then tell the clinic exactly what you did.

Don't test the joint with a hard chore. Let normal tasks show how it responds.

Everyday tasks show whether soreness has changed

Choose one change that would matter to you. It might be easier stairs or sounder sleep.

Write down what you can do before treatment. Memory can blur small changes over time.

Some people personally report less soreness afterward. Those personal reports can't predict your result.

Check the same task each week at home. Don't change the task from week to week.

Note both easier and harder days. You'll give the clinic a fair account.

Sources

1. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.

2. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

3. In a prospective randomized trial of 90 patients with Kellgren-Lawrence grade 1-3 knee osteoarthritis, bone marrow aspirate concentrate produced outcomes equivalent to - not better than - leukocyte-rich platelet-rich plasma through 24 months.

   Anz AW, et al. — Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial. Am J Sports Med, 2022. DOI: 10.1177/03635465211072554.

4. In a randomized trial of 118 knee osteoarthritis patients followed for 2 years with serial MRI, a single microfragmented adipose tissue injection and a single PRP injection produced statistically and clinically similar improvement - and the imaging showed no structural advantage for either.

   Zaffagnini S, et al. — Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. Am J Sports Med, 2022. DOI: 10.1177/03635465221115821.

5. A randomized trial comparing commercially available systems in 71 patients found microfragmented adipose tissue equivalent to leukocyte-rich PRP on KOOS pain at 12 months.

   Baria M, et al. — Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241233916.

6. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

7. A phase I single-arm study of 10 patients with chronic discogenic low back pain found a single intradiscal injection of adipose-derived MSCs with hyaluronic acid produced no procedure-related or cell-related adverse events over 12 months - a safety signal in 10 people, not an efficacy result.

   Kumar H, et al. — Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem Cell Res Ther, 2017. DOI: 10.1186/s13287-017-0710-3.

8. A CDC public health investigation confirmed culture-positive bacterial infections in 20 patients who received umbilical cord blood-derived products marketed as stem cell treatment between August 2017 and September 2018; whole-genome sequencing matched patient isolates to the product.

   Hartnett KP, et al. — Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies. JAMA Netw Open, 2021. DOI: 10.1001/jamanetworkopen.2021.28615.